Today: 28 January 2026
Subscribe
Browse Category

Cancer Research News 10 December 2025 - 12 January 2026

AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

New York, January 12, 2026, 13:31 EST — Regular session AbbVie Inc shares slipped Monday following news of a new collaboration with China’s RemeGen to co-develop an experimental solid-tumor drug, as the company ramps up efforts to expand its cancer portfolio via licensing deals. By 1:30 p.m. EST, AbbVie was down 0.6% at $218.81. (Reuters) Investors are focused on how…
12 January 2026
·····
Roche stock: $570 million MediLink cancer-drug deal puts Swiss shares back in focus

Roche stock: $570 million MediLink cancer-drug deal puts Swiss shares back in focus

ZURICH, Jan 11, 2026, 17:40 CET — The market has closed. Roche Holding shares rose 0.4% on Friday following news that China’s MediLink Therapeutics inked a licensing deal with the Swiss pharma giant for an experimental cancer drug. The stock closed at 340.80 Swiss francs on the SIX Swiss Exchange. (MarketWatch) The deal underscores how big pharma continues to invest…
11 January 2026
·····
Johnson & Johnson stock in focus: Trump drug-price pact and fresh cancer data before Monday

Johnson & Johnson stock in focus: Trump drug-price pact and fresh cancer data before Monday

New York, Jan 11, 2026, 10:45 EST — Market closed. Shares of Johnson & Johnson (JNJ.N) dipped 0.7% on Friday to $204.39 following the company’s announcement of a deal with the Trump administration to lower U.S. drug prices. In return, J&J secured exemptions from certain U.S. tariffs. The company said it will offer medicines at discounted rates via TrumpRx.gov and…
11 January 2026
·····
CG Oncology stock jumps 29% on faster Phase 3 PIVOT-006 data clock — what to watch next

CG Oncology stock jumps 29% on faster Phase 3 PIVOT-006 data clock — what to watch next

New York, January 10, 2026, 19:54 EST — The market has closed. CG Oncology Inc (CGON) shares surged nearly 29% on Friday, closing at $54.20 after hitting a session high of $57.36. The stock gained $12.25 during the day on volume of about 7.0 million shares. CG Oncology said it now expects “topline” Phase 3 results—the initial look at main…
11 January 2026
·····
Roche stock in focus after MediLink cancer-drug deal as investors eye Jan. 29 results

Roche stock in focus after MediLink cancer-drug deal as investors eye Jan. 29 results

ZURICH, Jan 10, 2026, 17:45 CET — Market closed Roche Holding (ROG.S) shares edged up on Friday, boosted by news that China’s MediLink Therapeutics secured another licensing deal with the Swiss pharma giant for a cancer drug candidate. Roche participation shares closed 0.4% higher at 340.80 Swiss francs on the SIX Swiss Exchange. (Medilink Therapeutics) Why it matters now: Roche…
10 January 2026
·····
Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update

Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update

NEW YORK, Jan 8, 2026, 08:39 EST — Premarket Shares of Immuneering Corp jumped about 24% to $8.33 in premarket trading on Thursday, after the biotech released updated survival data for its lead pancreatic cancer program. The stock last closed at $6.74. The update matters because Immuneering’s valuation hinges on whether atebimetinib can hold up as the company pushes toward…
8 January 2026
·····
GMAB stock slides as Genmab scraps late-stage acasunlimab cancer therapy

GMAB stock slides as Genmab scraps late-stage acasunlimab cancer therapy

NEW YORK, December 30, 2025, 1:54 PM ET — Regular session Genmab A/S’s U.S.-listed shares (GMAB) fell 3.3% to $31.45 in Tuesday’s regular session. The stock traded between $31.40 and $32.06 after opening at $31.98, with about 1.9 million shares changing hands. The move keeps attention on Genmab’s pipeline as investors reassess which late-stage assets can power growth. Dropping a…
30 December 2025
·····
JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next

JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next

NEW YORK, December 29, 2025, 20:26 ET — Market closed Johnson & Johnson (JNJ) shares were last down 0.02% at $207.56 on Monday after the healthcare conglomerate said it completed its $3.05 billion cash acquisition of cancer drug developer Halda Therapeutics. The stock traded between $207.31 and $209.46, and J&J said it will account for the deal as a business…
30 December 2025
·····
Nuvation Bio (NUVB) Soars After $18 Price-Target Hike – Is This High‑Growth Cancer Stock Still a Buy in 2025?

Nuvation Bio (NUVB) Soars After $18 Price-Target Hike – Is This High‑Growth Cancer Stock Still a Buy in 2025?

Nuvation Bio Inc. (NYSE: NUVB) has quietly morphed from an obscure penny stock into one of 2025’s wildest oncology stories. As of December 11, 2025, the stock is trading in the high single digits (around $7.8–$8.0), up roughly 200% year‑to‑date, following a string of clinical wins, a first drug approval, and a wave of fresh analyst upgrades. TipRanks The latest…
11 December 2025
····
Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

As of the session on 10 December 2025, Pfizer Inc. (NYSE: PFE) is trading around $25.5 per share, up modestly on the day and still far below its 2021 peak. The stock now combines a high dividend yield of roughly 6.5–7% with one of the cheapest valuations in big pharma, making it a focal point for income and value investors…
10 December 2025
···
GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

GSK plc (LSE: GSK; NYSE: GSK) is ending 2025 in full “pipeline flex” mode. On 10 December 2025 the company announced fresh US regulatory momentum for an experimental lung cancer drug and a new oncology collaboration, while the share price sits near multi‑year highs after a year of strong earnings and upgraded guidance. Stock Titan Below is a deep dive…
10 December 2025
····
Johnson & Johnson (JNJ) Stock After Hours on December 9, 2025: New Cancer Breakthrough, Dividend Payout and What to Watch Before the December 10 Open

Johnson & Johnson (JNJ) Stock After Hours on December 9, 2025: New Cancer Breakthrough, Dividend Payout and What to Watch Before the December 10 Open

Key Takeaways Below, we’ll walk through what happened to Johnson & Johnson stock after the bell on December 9 and what investors should watch before the U.S. market opens on Wednesday, December 10, 2025. 1. How Johnson & Johnson Stock Traded on December 9, 2025 Regular session: hot open, cold close On Tuesday, December 9, 2025, Johnson & Johnson shares:…
10 December 2025
····
1 2 3 4 5

Stock Market Today

  • Scotiabank Cuts Metro (TSE:MRU) Price Target Amid Mixed Analyst Views
    January 28, 2026, 3:38 PM EST. Scotiabank downgraded its price target for Metro (TSE:MRU) from C$110 to C$103, signaling a cautious outlook despite maintaining an 'outperform' rating. Other analysts show mixed sentiment: Royal Bank of Canada slightly raised its target to C$113 with a 'sector perform' rating, while TD Securities cut its price objective to C$113 but kept a 'buy' recommendation. Metro's stock traded lower at C$91.21, below its 50- and 200-day averages near C$98. The grocery and drugstore retailer recently reported quarterly earnings of C$1.16 per share and revenues of C$5.29 billion. Market consensus leans toward a 'hold' rating with an average target of C$106.25, reflecting cautious investor sentiment amid evolving price forecasts and steady financial performance.
Go toTop